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Abstract
Background: High-throughput screening (HTS) is one of the main strategies to identify novel entry points for the
development of small molecule chemical probes and drugs and is now commonly accessible to public sector
research. Large amounts of data generated in HTS campaigns are submitted to public repositories such as
PubChem, which is growing at an exponential rate. The diversity and quantity of available HTS assays and
screening results pose enormous challenges to organizing, standardizing, integrating, and analyzing the datasets
and thus to maximize the scientific and ultimately the public health impact of the huge investments made to
implement public sector HTS capabilities. Novel approaches to organize, standardize and access HTS data are
required to address these challenges.
Results: We developed the first ontology to describe HTS experiments and screening results using expressive
description logic. The BioAssay Ontology (BAO) serves as a foundation for the standardization of HTS assays and
data and as a semantic knowledge model. In this paper we show important examples of formalizing HTS domain
knowledge and we point out the advantages of this approach. The ontology is available online at the NCBO
bioportal http://bioportal.bioontology.org/ontologies/44531.
Conclusions: After a large manual curation effort, we loaded BAO-mapped data triples into a RDF database store
and used a reasoner in several case studies to demonstrate the benefits of formalized domain knowledge
representation in BAO. The examples illustrate semantic querying capabilities where BAO enables the retrieval of
inferred search results that are relevant to a given query, but are not explicitly defined. BAO thus opens new
functionality for annotating, querying, and analyzing HTS datasets and the potential for discovering new
knowledge by means of inference.
Background
High-throughput screening (HTS) has evolved into an
industrialized process and HTS of small molecules is one
of the most important strategies to identify novel entry
points for drug discovery projects [1]. Until about half a
decade ago, HTS and ultra-high throughput screening
(uHTS) have been primarily in the realm of the pharma-
ceutical industry where huge amounts of data have been
generated using these technologies. In 2003, NIH started
to make HTS and uHTS capabilities accessible to public
sector research via the Molecular Libraries Initiative [2]
to advance translational research [3] and specifically the
Molecular Libraries Program (MLP) [4]. MLP projects
leverage innovative assay technologies to develop
compounds effective at modulating biological processes
or disease states via novel targets. The program has
established publicly funded screening centers along with
a common screening library (the MLSMR, Molecular
Libraries Small Molecule Repository) and data repository,
PubChem [5]. Following a pilot phase, the Molecular
Libraries Probe Production Centers Network (MLPCN),
which consists of four comprehensive and three specia-
lized centers, has been running numerous screening
campaigns and has produced a wide range of chemical
probes [6]. Since 2004, the MLPCN centers have depos-
ited over two thousand HTS assays testing the effects of
several hundred thousand compounds. More recently a
European effort, EU Openscreen [7], to establish small
molecule screening capabilities is being developed.
Besides PubChem there are other data repositories
including ChEMBL [8], which includes data curated from
* Correspondence: sschurer@med.miami.edu
2Center for Computational Science, University of Miami, Miami, FL, USA
Full list of author information is available at the end of the article
Visser et al. BMC Bioinformatics 2011, 12:257
http://www.biomedcentral.com/1471-2105/12/257
© 2011 Visser et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.the medicinal chemistry literature, and the Psychoactive
Drug Screening Program (PDSP) [9] with mostly receptor
and ion channel binding assay results. The MLP is cur-
rently the largest public screening effort. The pace with
which novel biological assay and HTS results are being
s u b m i t t e ds u g g e s t st h a tw eh a v eo n l yb e g u nt oe x p l o r e
the scope of possible assay formats and technologies to
interrogate complex biological systems.
Similar to the HTS datasets produced in the pharmaceu-
tical industry, the public sector screening data represent
an invaluable resource, which has received wide-spread
attention (including from the pharmaceutical companies).
However, their diversity and quantity also present enor-
mous challenges to organizing, standardizing, and inte-
grating the data with the goal to maximize their scientific
and ultimately their public health impact as the screening
results are carried forward into drug development pro-
grams. Despite calls for HTS standards [10], there have
been no public initiatives defining minimum specifications,
data exchange formats, or a controlled terminology. This
situation lies in contrast to other fields such as microarray
experimentation, where minimum information specifica-
tions (Minimum information about a Microarray Experi-
ment or MIAME 2.0), multiple data models (MicroArray
Gene Expression Object Model or MAGE-OM) and the
MGED (Microarray and Gene Expression Data) ontology
[11] have been developed and incorporated into Web Ser-
vices such as the Gene Expression Omnibus [12] to facili-
tate data exchange. PubChem [13] was set up with
flexibility in mind and is able to collect almost any type of
assay results. Screened compounds and substances are
represented seamlessly by chemical structure files and per-
tinent assay data are interlinked to other NCBI resources.
However, PubChem has limitations that burden data
retrieval and meta-analysis. Foremost is an unstructured/
semi-structured data representation format that is largely
determined by the submitter. Information regarding assay
formats (e.g. cell-based vs. biochemical), readout technolo-
gies, reagents employed, and details of the biological sys-
tem interrogated are represented as free text. This makes
it impossible to query PubChem by simple, yet relevant
concepts, such as “luciferase reporter gene assays” or
“GPCR agonist assays”.
To describe compound activities, PubChem uses two
terms, “Outcome” and “Score”, that have different conno-
tations depending on the submitter. This discrepancy
effectively renders quantitative comparisons between
assays impossible. Additional terms describing assay
results (referred to as assay endpoints in this paper), such
as the half maximal inhibitory concentration (IC50), have
different nomenclatures. For example, “JAK2V617F Inhi-
bition (IC50) “ (AID 2165), “mutant luminescence Mean
IC50” (AID 792), “Best-Fit Value IC50 (uM) “ (AID
1916), “IC50_Mean” (AID 2784), “Mean IC50” (AID
1695) are all equivalent endpoints for the purpose of ana-
lysis, but are distinct in the repository. This system has
led to the accumulation of over 17,000 unique endpoints
that cannot be compared without large-scale annotation
efforts. In addition to inconsistent naming, there is no
semantic description of screening endpoints. In this
paper, we show how the definition of endpoints (such as
“IC50”) in an ontology with formal semantics facilitates
the retrieval of data that are relevant to a search query,
but not explicitly defined by the query terms (inferred
results).
Ontologies have traditionally been used in biology to
organize information within a domain and, to a lesser
extent, to annotate experimental data. A successful and
highly-used biomedical ontology is the Gene Ontology
(GO) [14], which consists of a taxonomy of terms describ-
ing gene product localization and function. Several hun-
dred ontologies are hosted by the Open Biological and
Biomedical Ontologies (OBO) Foundry (102, counted on
4/15/2011) [15] as well as the National Center for Biome-
dical Ontologies (NCBO, 263 ontologies counted on 4/15/
2011) [16], centered on domains ranging from African tra-
ditional medicine to Zebra fish anatomy. A closer look
reveals that the majority of these ontologies are actually
taxonomies or “enriched taxonomies” (with comments for
understanding). It has been suggested that the general uti-
lity of many of these ontologies is likely overestimated,
because terms lack clear semantics and multiple conven-
tions are used to describe overlapping information [17]. In
addition, many of the biomedical ontologies so far have
not made use of available description logic (DL) features
of the Web Ontology Language (OWL), the official ontol-
ogy language recommended by the World Wide Web
Consortium (W3C).
In this paper we describe a novel approach to standar-
dize, organize and semantically define biological assays
and screening results such as those in PubChem, and
which addresses many of the challenges raised above.
We briefly discuss the main components required to
describe important details of bioassay experiments and
screening results. We illustrate the architecture of the
BioAssay Ontology (BAO) and show examples of how
some of the concepts are implemented in BAO to serve
as a standard and as a knowledge model.
BAO is organized by several main concepts, which
describe important characteristics of assays and by which
assays can be meaningfully categorized. One of the goals
of BAO is to enable the classification of assays by relevant
categories so that related assays can quickly be identified,
for the purpose of data analysis or assay development [18].
These main categories relate to questions like: i) What
type of perturbing agent (perturbagen) was screened? ii)
What was the main biological/chemical category (format)
of the assay? iii) How was the perturbation converted into
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method of signal detection? v) What was the biological
context (meta target) of the assay? vi) How were the
results reported/quantified?
A full description of BAO is beyond the scope of this
paper and will be reported elsewhere. For details we
refer to the BAO website [19]. A novel feature of BAO
is that it supports inferences within the functionality of
OWL 2.0, raising the possibility of automated knowledge
acquisition from existing datasets. We present a number
of semantic query scenarios that are enabled by BAO. In
addition to identifying assays and data by concepts in
the ontology, we show how our approach can retrieve
inferred results that are highly relevant to a query, but
would not match the search term explicitly and there-
fore could not be easily identified by a classical (rela-
tional) search. These type of queries are made possible
by the standardization that is provided via BAO and the
reasoning/inference capabilities of the system.
Results and Discussion
Main concepts of the BioAssay Ontology and curation of
PubChem assays
BAO describes biological screening assays, in which the
perturbation of a biological system or a component
thereof (relative to a reference state) by a perturbagen is
detected and in many cases quantified. An example for a
simple assay is the inhibition of an enzyme by a small
molecule, which would be detectable by quantifying the
product of the enzymatic reaction. For example inhibition
o fak i n a s ec o u l db ed e t e c t e dv i aa na n t i b o d ys p e c i f i ct o
the phosphorylated substrate (a kinase catalyzes the phos-
phorylation of a substrate by ATP). In one assay design,
the antibody is linked with a fluorescence resonance
energy transfer (FRET) donor and the (kinase) substrate
with a FRET acceptor. A fluorescence signal of the FRET
acceptor is only generated if donor and acceptor are in
proximity, i.e. if the substrate is phosphorylated. If the
kinase is inhibited by a small molecule perturbagen, the
signal decreases. An implementation as homogeneous
time resolved FRET (HTRF) assay is applicable to high
throughput screening. Countless sophisticated biological
screening assays to interrogate simple to complex biologi-
cal systems have been developed.
With BAO we aim to develop an open standard for
the description of HTS and microscopy-based high-con-
tent screening (HCS) assays and data for the purpose of
classification and analysis. To describe biological screen-
ing experiments such as those deposited in PubChem,
we first identified the main categories that need to be
captured in order to meaningfully compare data from
different biological screening experiment. These compo-
nents are perturbagen, format, design, detection technol-
ogy, meta target, endpoint, which are described here:
Perturbagen
Assay “perturbagen” refers to the agent that directly
interacts or indirectly affects the meta target of a bioas-
say. PubChem assays predominantly have small mole-
cules as perturbagens; however the concept perturbagen
in BAO includes various other perturbing agents,
including, nucleic acid (e.g. siRNA, cDNA), lipid, or pro-
teins. Perturbagen specifications include perturbagen
source and details on its delivery.
Assay Format
The assay “format” is a higher-level assay category that
relates to the biological and chemical features that are
common to each test condition in the assay. Assay format
includes several broad categories. “Biochemical format”
describes assays that are performed with a purified pro-
tein, such as the example above. “Cell-based format”
r e l a t e st oa s s a y st h a ta r ep e rformed with living cells.
“Organism-based format” refers to assays with a living
organism. Other common formats include “cell-free
format”, “tissue-based format”, and “physicochemical for-
mat”. Additional format specifications are captured that
describe, for example, whether the assay is homogeneous
or heterogeneous in nature.
Assay Design and Detection Technology
The assay “design” describes the methodology to report
the action of the perturbagen on the target; i.e. how the
perturbation is converted into a detectable signal. In
BAO, assay design is broadly classified into one of eight
categories: “binding reporter”, “enzyme reporter”, “indu-
cible reporter”, “morphology reporter”, “viability repor-
ter”, “redistribution reporter”, “conformation reporter”,
and “membrane potential reporter”. We further anno-
tated the readout “detection technology” used in the
assays. These annotations fa l li n t oo n eo fs e v e r a lc a t e -
gories, including “spectrophotometry”, “fluorescence”,
“luminescence”, “label free technology”, “scintillation
counting”,a n d“microscopy”. Further specifications of
assay design and detection technology can include the
assay kit or detected wavelength.
Assay Meta Target
Assay “meta target” is a description of the component(s)
of the biological system that interact with the perturba-
gen. Meta target can be directly described as a molecular
entity (e.g. a purified protein or a protein complex), or
indirectly by a biological process or event (e.g. phosphor-
ylation), or a signaling pathway. An important aspect of
our meta target annotations is that they are embedded
with semantic information (e.g. “is target of” only “mea-
sure group”; disjointness with classes such as “perturba-
gen” or “endpoint”). Meta target may be further linked to
additional terms and external content, such as a pathway
database. One of the goals of describing meta targets is
to infer possible molecular targets or perturbagen
mechanisms of action based on the analysis of results of
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protein modifications, cell lines, or details about the
mechanism of ligand-protein interaction.
Assay Endpoint
An assay “endpoint” describes a quantitative or qualitative
outcome of the bioassay. The main classes that we identi-
fied are “perturbagen concentration”-a n d“response”-type
endpoints. Simple examples include IC50, EC50, CC50
and percent inhibition, percent activation, percent viabi-
lity, respectively. We conducted two stages of endpoint
formalization, the first of which was to standardize the
endpoint names in PubChem by manual curation. This
reduces the number of different representations of each
endpoint concept. In the examples illustrated below we
have reduced 85 unique PubChem endpoint representa-
tions to 18 standardized endpoints. However, it is not pos-
sible (by manual curation) to uniquely describe each
endpoint by exactly one representation, because the end-
point concept depends on other assay concepts and can
even vary among different perturbagens of the same assay.
In BAO, we therefore defined the endpoint concepts
semantically using description logic to specify relation-
ships among the endpoint types and other BAO concepts
(see below, Ontology-facilitated query examples, example
3). This enables us to retrieve inferred results, which could
otherwise not be obtained or would require complex Boo-
lean endpoint queries. An excerpt of BAO around the
class assay endpoint is shown below (Ontology outline,
development and implementation).
For the purpose of demonstrating the semantic query-
ing capabilities facilitated by BAO (which are described
below) we curated over 300 bioassays from PubChem
and standardized the endpoints using BAO.
Ontology outline, development and implementation
BAO was designed to describe biological screening
experiments and their outcomes by the six main compo-
nents outlined above, in addition to general assay attri-
butes that don’t fall into any of these categories. Each
BAO component includes multiple levels of sub-classes
and specification classes which are linked via object prop-
erty relationships to form a knowledge representation. A
full description of this schema will be discussed else-
where; the current version of the ontology (v1.2b868), is
available on our website and at the NCBO bioportal. Our
development approach follows established ontology engi-
neering methodologies using a combination of top-down,
domain expert-driven and bottom-up, data-driven
approaches [20]. The current version of BAO consists of
730 OWL 2.0 [21] classes, 72 object properties (rela-
tions), 7 data properties, and 25 individuals (not includ-
ing any annotated assays). Sev e r a le x t e r n a lo n t o l o g i e s
contain partial information of some of the components
of biological assays described by BAO. To leverage these
efforts, we have imported into BAO relevant sections
from Gene Ontology (GO) [14], Cell Line Ontology
(CLO) [22], Unit Ontology (UO) [23] and others. GO
biological process terms and CLO cell line names and
additional parameters are used in BAO meta target and
meta target specifications. Organism names associated
with targets were imported from NCBI taxonomy. Pro-
tein target names and IDs were referenced from UniProt.
From UO we imported concentration unit and time unit
terms. We are currently working on mapping BAO to
other OBO ontologies. For example, OBI includes rele-
vant information to describe biological assays [24]. We
have mapped some of the BAO relationships to the OBO
Relationship Ontology (RO) [25] and we aim to make
more use of RO relationships in the future. Additionally,
we may be able to use RO to map BAO concepts to other
ontologies, in particular OBI. BAO is “rich” with a DL
expressivity of ALCHOIQ(D). This means that the ontol-
ogy has the basic S (ALC) expressivity [26] with role hier-
archies (H), nominals (O), inverse properties (I), qualified
cardinality restrictions (Q), and the use of datatype prop-
erties, data values or data types (D). It should be noted
that three major bioinformatic terminology bases:
SNOMED [27], Galen [28], and GO [14] have the expres-
sivity of EL, with additional role properties. In EL, only
intersections between concepts and full existential quan-
tification are possible. In comparison, BAO is a signifi-
cant improvement in expressivity.
Figure 1 illustrates the high-level outline of BAO. It
shows the root-level classes, which are described above
and general bioassay specifications, and some of their
relationships. Some concepts (format, perturbagen and
bioassay specifications) are linked directly to bioassay
while others (endpoint, meta target, design, detection
technology) are linked via a measure group to accommo-
date multiplexed and multi-parametric assays. It is also
important to note that the assay components are not
modeled as sub-classes of bioassay, because they do not
have a formal “is a“ relationship to bioassay. The bioassay
component specification classes are not shown. Figure 2
shows an excerpt of the BAO classes (and their subsump-
tion hierarchies) that are related to the concept “end-
point”. For example Figure 2 illustrates the different type
of endpoints, such as concentration- and response-type
and also the relationships to the specification class,
which includes (among others) “endpoint mode of
action” with various sub-classes. These concepts are rele-
vant for the semantic querying and reasoning capabilities
described in the examples below.
The complete specification in OWL 2.0 can be visually
explored and downloaded from our web page http://www.
bioassayontology.org/visualize/. To illustrate how each of
these classes is embedded with semantic information, the
following example depicts a detailed specification for the
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gen that results in 50% inhibition.
Equivalent classes
ic50 ≡ (∃"has has mode of action”.inhibition) ⊓
(∀"has mode of action”.inhibition) ⊓
("has percent response”. “50 percent inhibition
individual”)
Superclasses
ic50 ⊑ (∀“has curvefit spec”. “curvefit spec”)
ic50 ≡ “perturbagen concentration”
Inherited anonymous classes
ic50 ⊑ (∃“has perturbagen concentration unit”. “concen-
tration unit”) ⊓
(∀“has perturbagen concentration unit”."concentra-
tion unit”) ⊓
(= 1“has perturbagen concentration value”.xsd: float)
⊓
(∀"has specification”."endpoint spec”) ⊓
(∃"has perturbagen”.perturbagen) ⊓
(= 1"has perturbagen”.T)
Symbols
≡: equivalentClass, ⊑: subClassOf, ∀: allValuesFrom, ∃:
someValuesFrom, = N: exactly N, T: Thing.
It is important to note that in OWL 2.0, there are only
definitions for equivalent classes (necessary & sufficient
conditions), and superclasses (necessary conditions).
Necessary and sufficient conditions are used to classify
individuals; for example we might be able to infer that an
individual endpoint must be an IC50 because the mode of
action is inhibition (among other criteria). With only
necessary conditions, the definition is logically different,
saying that if an individual is a member of the class IC50,
it is necessarily a sub-class of “perturbagen concentration”.
The equivalent class IC50 specifies “has mode of action”
only “inhibition”. “Only” here denotes universal quantifica-
tion, describing all the individuals whose “has mode of
action” relationships refer to members of the class inhibi-
tion; or conversely, the individuals that do not have “has
mode of action” relationships to individuals that are not
members of the class “inhibition”. There are also existen-
tial restrictions that can be seen as “among other things”,
and are used to close a given property, which is necessary
for the reasoning process. The keyword “some” denotes
existential restrictions. An example in our ontology is “has
mode of action” some “inhibition”. This specifies the exis-
tence of at least one relationship along a given property to
an individual, which is a member of the class IC50.
Certain specifications are inherited from classes that
are higher up in the class hierarchy. An example of this
is the inherited anonymous class definition of indivi-
duals having the object property “has perturbagen con-
centration value”. There is also the relationship “has
perturbagen”, describing that every individual of the
IC50 class must have at least one perturbagen.
Figure 1 BAO excerpt showing the root-level classes and some of their relationships.
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The work flow for applying the ontology to real data from
PubChem is illustrated in Figure 3. First, we have summar-
ized a set of attributes about the assays that needed to be
annotated. We have considered >120 attributes (e.g.,
“EndpointStandardized”, which takes values of IC50, per-
cent inhibition, fold activation, etc.). These attributes are
populated row-by-row in a spreadsheet for the relevant
assays using a local mirror of the PubChem data source. A
major portion of the spreadsheet is curated manually. In
Figure 2 A view on some of BAO’s concepts, defined as either primitive (light gray/yellow) or defined classes (dark gray/orange).
Visser et al. BMC Bioinformatics 2011, 12:257
http://www.biomedcentral.com/1471-2105/12/257
Page 6 of 16order to compensate for the errors that may have been
introduced during the manual work, we have written a
software module to cross-reference each entry in the
spreadsheet with the PubChem data source. There were
some redundant information among the annotation
spreadsheet and data in PubChem, for example screening
concentration reported in the assay description (which
was manually curated) and the screening concentration
deposited to PubChem (which was available in the mirror
data source). Some information in the annotation template
was explicitly repeated from PubChem in order to cor-
rectly map annotated (standardized) terms to data in Pub-
Chem, for example to standardize endpoints. This
redundancy can be seen as a quality control step to
uncover any discrepancies between original and curated
data. This step has revealed some inconsistencies in the
PubChem database, such as PubChem table entries that
are not atomic, incorrect or missing screening concentra-
tions or units; and it has also helped to minimize the
errors that had been made throughout the cumbersome
curation process. Second, we have developed a core soft-
ware module, described as Loader/Bootstrap in Figure 3,
which reads the curated and quality-checked data and
then uses the ontology as well as necessary PubChem data
to create a logical model of the domain. The reasoning
engine Pellet was used, both to create and query the
domain model. Pellet is a server-based OWL-DL reasoner
that supports SROIQ(D). We also experimented with
other DL reasoners, such as HermiT and FaCT++, but
used Pellet because of its existing API (Application Pro-
gramming Interface) that allows interfacing to other soft-
ware components that we use.
Of particular note here is the BAO expressivity of
SROIQ(D). S allows atomic and complex concept nega-
tion, concept intersection, universal restrictions, limited
existential quantification and transitive roles. R stands
for limited complex role inclusion axioms; reflexivity,
irreflexivity and role disjointness. O stands for nominals,
I for inverse properties, Q for qualified cardinality
restrictions and (D) for the use of datatype properties or
data values. The reasoner checks the internal consis-
tency of the logical model and inferred hidden knowl-
edge. One example for this is the class AC50, which was
inferred to be a superclass of IC50 (see Figure 4b). The
Figure 3 BAO software modules (orange/dark gray), documents and databases (light green/light gray).
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tion of the perturbagen that results in either 50% activa-
tion (EC50) or inhibition (IC50). Figures 4a and 4b
show the asserted and inferred models of AC50,
respectively.
Ontology-facilitated query examples
We performed a series of experiments based on 194 out
of the 300 curated PubChem bioassays that had the
(standardized) endpoint terms IC50, EC50, AC50, per-
cent activation, percent stimulation and percent inhibi-
tion. Since the entire set of assays and endpoints would
have required > 17 GB worth of RDF triples, we decided
to limit the amount of considered endpoints to 20 for
performance reasons. Future versions of the software will
focus on optimization and the use of additional annota-
tions. With 20 endpoints, the software generated 45,075
triples (asserted ontology + triple database) in the Jena
store. All example queries can be found and tested online
at http://baoquery.ccs.miami.edu/joseki/query.html. The
reasoner classifies the individuals and SPARQL allows an
efficient search through this inferred graph.
Example 1: This example illustrates a common query
for compounds with an IC50 value of less than a certain
cutoff (here ≤ 10 μM). Such a query should also return
results of differently named IC50 endpoints (e.g. AC50),
which a user may not know exist. A user querying the
database may also be interested in returning other rele-
vant endpoints, such as IC80 values ≤10 μM( i ft h e y
existed in the repository) or other result types such as
potent inhibitors screened at less than the IC50 concen-
tration. With the semantic definition of IC50 above, we
can achieve both. Query: return all compounds from
assays with an inhibitory mode of action and that have a
percentage response of 50% or greater at ≤10 μM
screening concentration.
The SPARQL query was the following:
PREFIX rdf: <http://www.w3.org/1999/02/
22-rdf-syntax-ns#>
PREFIX rdfs: <http://www.w3.org/2000/
01/rdf-schema#>
PREFIX xsd: <http://www.w3.org/2001/
XMLSchema#>
PREFIX owl: <http://www.w3.org/2002/07/
owl#>
PREFIX bao: <http://www.bioassayontol-
ogy.org/bao#>
# results
SELECT DISTINCT ?compound ?endpoint ?
type ?responseValue ?screeningConc ?assay
WHERE {
# from endpoints
?endpoint rdf:type bao:BAO _0000179.
?endpoint bao:BAO_ 0000196 ?inhibition.
# has a mode of action inhibition
?inhibition rdf:type bao:BAO _0000091.
# perturbagen concentration endpoint
?endpoint bao:BAO _0000336 ?
screeningConc.
Figure 4 a) Asserted logical taxonomy for AC50 (above) and b) Inferred logical taxonomy, where IC50 is classified as a sub-class of
AC50.
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Page 8 of 16# has concentration unit micro molar
?endpoint bao:BAO_0000183 bao:
BAO_0000107.
# has percent response
?endpoint bao:BAO _0000337 ?
percentResponse.
?percentResponse bao:BAO_ 0000195 ?
responseValue.
?endpoint rdf:type ?type.
?type rdfs:subClassOf bao:BAO_ 0000180.
# response endpoint
UNION {
?endpoint bao:BAO_ 0000196 ?
inhibition.
?inhibition rdf:type bao:BAO_
0000091.
?endpoint bao:BAO_ 0000338 ?pert.
?pert bao:BAO_0000183 bao:BAO_
0000107.
?pert bao:BAO _0000336 ?
screeningConc.
?pert bao:BAO_0000183 bao:BAO_
0000107.
?endpoint bao:BAO_0000195 ?
responseValue.
?endpoint rdf:type ?type.
?type rdfs:subClassOf bao:BAO_
0000181.
}
?endpoint bao:BAO_0000185 ?compound.
?endpoint rdf:type ?type.
?assay bao:BAO _0000209 ?measureGroup.
?measureGroup bao:BAO_ 0000208 ?
endpoint.
# screening concentration <= 10 micro
molar && # percent
# response >= 50%
FILTER(?screeningConc <= 10 && ?respon-
seValue >= 50)
}
The BAO software returns 2,741 SPARQL endpoint
results from the inferred model residing in the triple
store, 4 of which are shown below for illustrative pur-
poses. All results are individuals with a working internal
resource identifier (IRI), which corresponds to a URI,
but is valid only internally. IRIs are abbreviated due to
space limitations, but all complete IRIs are available via
http://baoquery.ccs.miami.edu/joseki/query.html
(5) (?compound=<bao#individual_
BAO_0000021_2858522>)
(?endpoint=<bao#individual_BAO_
0000190_2_2357>)
(?type=<bao#BAO_ 0000190>)
(?responseValue="50”
^^xsd:float)
(?screeningConc="4.0”
^^xsd:float)
(?assay=<bao#individual_BAO_
0000015_1293>)
(17) (?compound=<bao#individual_BAO_
0000021_133407>)
(?endpoint=<bao#individual_BAO_
0000190_2_2533>)
(?type=<bao#BAO_ 0000190>)
(?responseValue="50”
^^xsd:float)
(?screeningConc="8.59”
^^xsd:float)
(?assay=<bao#individual_BAO_
0000015_2409>)
(24) (?compound=<bao#individual_BAO_
0000021_11057>)
(?endpoint=<bao#individual_BAO_
0000190_2_4122>)
(?type=<bao#BAO_ 0000186>)
(?responseValue="50”
^^xsd:float)
(?screeningConc="6.3096”
^^xsd:
float)
(?assay=<bao#individual_BAO_
0000015_948>)
(2690) (?compound=<bao#individual_BAO_
0000021_657680>)
(?endpoint=<bao#individual_BAO_
0000201_1_1670>)
(?type=<bao#BAO_ 0000201>)
(?responseValue="63.48”
^^xsd:float)
(?screeningConc="4.0”
^^xsd:float)
(?assay=<bao#individual_BAO_
0000015_834>)
Results are shown by their unique IRIs, e.g. the first
result contains the compound ID (CID) 2858522 [29] of
an individual of the class perturbagen (BAO_0000021).
The SPARQL query also selects for the endpoints of the
perturbagens that fulfill the activity criteria. The query
retrieves results that classify as specific types of end-
points (subsumption reasoning). Result (5) (CID
2858522, AID 1293) was found because IC50 (note, that
in PubChem AID 1293 this endpoint has been incor-
rectly reported as EC50; we corrected this during the
curation process) (BAO_0000190) is_a perturbagen con-
centration-type endpoint (as defined above). Result (17)
(CID 133407, AID 2409) also returns IC50. Result (18)
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with the (inferred) subsumption hierarchy (compare
Figure 4b). Querying AC50 (instead of IC50) thus would
also retrieve this result. Result (24) (CID 11057, AID
948) is an AC50 endpoint (named “potency” in Pub-
Chem); result (23) returns the same data as IC50 (not
shown) - again consistent with the inferred class hierar-
chy. Result (2690) (CID 657680, AID 1834) is a percen-
tage inhibition endpoint (63.5%) and the screening
concentration is 4 μM (i.e. less than the query 10 μM).
These different types of results can be retrieved because
of the subsumption reasoning of the DL engine using
formally defined endpoints. This example illustrates that
with the endpoint definition in BAO, we can identify
and return relevant query results, which are not
restricted to a specific endpoint type or endpoint repre-
sentation (that is specified by the query), as it would
typically be the case in a relational system.
Example 2: Here, we illustrate an example of con-
structive reasoning in identifying compounds of a parti-
cular pharmacological action. Query: return all assays
with compounds that have a mode of action “activation”
and show a percentage response of ≥ 50% at ≤ 10 μM
screening concentration. The query syntax was the fol-
lowing (we are omitting the PREFIX section this time):
SELECT DISTINCT ?compound ?endpoint ?
type ?moaType ?responseValue ?screening-
Conc ?assay
WHERE {
# from endpoints
?endpoint rdf:type bao:BAO_0000179.
?endpoint bao:BAO_ 0000196 ?activation.
# has a mode of action activation
?activation rdf:type bao:BAO_ 0000087.
?activation rdf:type ?moaType.
?moaType rdfs:subClassOf bao:BAO_
0000084.
# perturbagen concentration endpoint
?endpoint bao:BAO_ 0000336 ?
screeningConc.
# has concentration unit micro molar
?endpoint bao:BAO_0000183 bao:
BAO_0000107.
# has percent response
?endpoint bao:BAO_0000337 ?
percentResponse.
?percentResponse bao:BAO_0000195 ?
responseValue.
?endpoint rdf:type ?type.
?type rdfs:subClassOf bao:BAO_0000180.
# response endpoint
UNION {
?endpoint bao:BAO_ 0000196 ?
activation.
?activation rdf:type bao:BAO_
0000087.
?activation rdf:type ?moaType.
?moaType rdfs:subClassOf bao:BAO_
0000084.
?endpoint bao:BAO_0000338 ?pert.
?pert bao:BAO_0000183 bao:BAO
_0000107.
?pert bao:BAO _0000336 ?
screeningConc.
?pert bao:BAO_0000183 bao:BAO_
0000107.
?endpoint bao:BAO _0000195 ?
responseValue.
?endpoint rdf:type ?type.
?type rdfs:subClassOf bao:BAO_
0000181.
}
?endpoint bao:BAO_0000185 ?compound.
?endpoint rdf:type ?type.
?assay bao:BAO _0000209 ?
measureGroup.
?measureGroup bao:BAO_ 0000208 ?
endpoint.
# screening concentration <= 10 micro
molar && # percent
# response >= 50%
FILTER(?screeningConc <= 10 && ?
responseValue >= 50)
}
Similar to example 1, the system returns different
types of relevant results. In addition to assays with com-
pounds that have an endpoint “percent activation” of
50% at <10 μM, this query also returns assays with an
EC50 or an AC50 value of <10 μM. Moreover, this
example demonstrates one of the constructive reasoning
mechanisms in BAO where “activation” was defined as
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classes, e.g. agonist). As the reasoning system returns
results that satisfy the original query and the inferred
query, searching “activation” (BAO_0000087) returns
exactly the same results as querying for “stimulation”
(BAO_0000093) independent from the specific term
used to describe the pharmacological action. Selected
results are:
(1) (?compound=<bao#individual_BAO_
0000021_653469>)
(?endpoint=<bao#individual_BAO_
0000188_2_5524>)
(?type=<bao#BAO_ 0000180>)
(?moaType=<bao#BAO_ 0000087>)
(?responseValue="50”
^^xsd:float)
(?screeningConc="2.154”
^^xsd:float)
(?assay=<bao#individual_BAO_
0000015_695>)
(5) (?compound=<bao#individual_BAO_
0000021_653469>)
(?endpoint=<bao#individual_BAO_
0000188_2_5524>)
(?type=<bao#BAO _0000188>)
(?moaType=<bao#BAO_ 0000093>)
(?responseValue="50”
^^xsd:float)
(?screeningConc="2.154”
^^xsd:float)
(?assay=<bao#individual_BAO_
0000015_695>)
(5130) (?compound=<bao#individual_BAO_
0000021_645132>)
(?endpoint=<bao#individual_BAO_
0000200 1_464>)
(?type=<bao#BAO_ 0000181>)
(?moaType=<bao#BAO_ 0000087>)
(?responseValue="132.52”
^^xsd:
float)
(?screeningConc="5.7”
^^xsd:float)
(?assay=<bao#individual_BAO_
0000015_1318>)
(5131) (?Compound=<bao#individual_BAO_
00000021_645132>)
(?endpoint=<bao#individual_BAO_
0000200_1_464>)
(?type=<bao#BAO_ 0000200>)
(?moaType=<bao#BAO_ 0000093>)
(?responseValue="132.52”
^^xsd:
float)
(?screeningConc="5.7”
^^xsd:float)
(?assay=<bao#individual_BAO_
0000015_1318>)
The first result (1) refers to AID 695 [30]. As before,
the formal definition of “mode of action” in the ontology
and the reasoning system make it possible to retrieve
relevant results by inference, which could not be
returned from a relational database system (e.g. agonist
if one searched for activation).
Example 3: With this example, we demonstrate a spe-
cific case concerning three concepts: endpoint, bioassay,
and perturbagen. Figure 5 shows the relevant relation-
ships between these concepts (note: the concept “mea-
sure group” exists to accommodate multiplexed assays;
i ti sn o tu s e di nt h i se x a m p l e ) ;i ti sam o r ed e t a i l e d
representation of some of the concepts in Figure 1. Of
particular interest is the relation “has perturbagen” that
holds between endpoint and perturbagen as well as
bioassay and perturbagen. The ontology specifies that
this property has an inverse relationship with “is pertur-
bagen of”. Here we show how these relationships (with
their characteristics) are used to retrieve eligible
instances (individuals) by inference. This reasoning
mechanism thus makes it possible to retrieve perturba-
gens based on more complex concepts, for example a
class of promiscuous compounds (compounds that are
active in several assays - see below).
To illustrate this, we queried for all perturbagens that
have a percentage response of ≥50% in at least three
assays. The SPARQL query was as follows:
SELECT ?pert
WHERE
{ ?pert rdf:type bao:BAO_ 0000021.
?pert bao:BAO_ 0000361 ?assay.
?assay bao:BAO_ 0000209 ?measureGroup.
?measureGroup bao:BAO_ 0000208 ?
endpoint.
?endpoint bao:BAO_ 0000195 ?
percentResponseValue.
} UNION
{ ?pert rdf:type bao:BAO_ 0000021.
?pert bao:BAO_ 0000361_?assay.
?assay bao:BAO _0000209 ?
measureGroup.
?measureGroup bao:BAO_ 0000208 ?
endpoint.
?endpoint bao:BAO_ 0000337 ?
percentResponse.
?percentResponse bao:BAO_ 0000195 ?
percentResponseValue.
}
FILTER (?percentResponseValue >= 50)
}
GROUP BY ?pert
HAVING (count(distinct ?assay) >= 3)
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gen of”, which points to either an endpoint or a bioassay.
The query separately checked for bioassay instances and
endpoint instances. The syntax allowed for the expression
of the notion of “at least” in a simple way. Specifically, we
used the syntactic extensions available in the ARQ
SPARQL [31] implementation. The “GROUP BY” extended
clause grouped the unique “?pert” result set (?pert is a vari-
able here) in a row-by-row basis. The “HAVING” clause
applied the lter “count(distinct ?assay))” to the result set
after grouping. The results of the query were as follows.
First, we queried for the compound and obtained:
(1) (?pert=<bao#individual_BAO_
0000021_646704>)
We then used this result (bao:individual_BAO_
0000021_646704) for the next query:
SELECT ?assay ?percentResponseValue
WHERE
{ bao:individual_BAO_ 0000021_646704
bao:BAO_ 0000361 ?assay.
?assay bao:BAO_ 0000209 ?mg.
?mg bao:BAO_ 0000208 ?endpoint.
bao:individual_BAO_ 0000021_646704
bao:BAO_ 0000361 ?endpoint.
?endpoint bao:BAO_ 0000195 ?
percentResponseValue.
} UNION
{ bao:individual_BAO_0000021_
646704bao:BAO_ 0000361 ?assay
?assay bao:BAO_ 0000209 ?mg.
Figure 5 Relationships between BioAssay, EndPoint, and Perturbagen.
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Page 12 of 16bao:individual_BAO_0000021_646704
bao:BAO_0000361 ?endpoint.
?endpoint bao:BAO_0000337 ?
percentResponse.
?percentResponse bao:BAO_000195 ?
percentResponseValue.
}
FILTER (?rv >= 50)
}
Here are the final results:
(1) (?assay=<bao#individual_BAO_
0000015_1262>)
(?percentResponseVa-
lue="116.84”
^^xsd:float)
(2) (?assay=<bao#individual_BAO_
0000015_1306>)
(?percentResponseVa-
lue="106.48”
^^xsd:float)
(3) (?assay=<bao#individual_BAO_
0000015_1316>)
(?percentResponseVa-
lue="99.42”
^^xsd:float)
Example 3 is a simple illustration to identify com-
pounds with a specific profile (here, active in three
assays). The query actually retrieved inferred informa-
tion, facilitated by the inverse relationship “is perturba-
gen of”. Further specification of this query, e.g. by BAO
meta target or design sub-classes, would allow to quickly
identify individuals based on more complex concepts,
for example compounds that are promiscuously active
in assays of a specific design and which are therefore
likely artifacts.
The three query examples illustrate some of the fea-
tures that can be used in complex search queries with
an underlying DL-based ontology. Other features such
as role hierarchies, quantifiers, nominals etc. were also
used in our ontology.
Conclusions
We have developed an ontology to describe biological
assay and screening results. The BioAssay Ontology
(BAO) provides a foundation for standardizing assay
descriptions and endpoints and serves as a knowledge
model by describing screening experiments and results
semantically using description logic (OWL language).
BAO facilitates semantic search capabilities enabling the
retrieval of data that are relevant to a query and that could
not be readily obtained otherwise. 300 PubChem assays
were curated and 194 were loaded into a triple store to
demonstrate various search scenarios. The ontology was
published (current version 1.2b868) and is available at
http://bioassayontology.org and the NCBO bioportal. This
is the first ontology to describe this domain, and certainly
the first time that bioassay and HTS data have been repre-
sented using expressive description logic. There are
numerous advantages to this approach; most importantly
it opens new functionality for querying and analyzing HTS
datasets and the potential for discovering knowledge that
is not explicitly represented, by inference. We demon-
strated these novel capabilities and their benefits by three
simple examples of how specific features of our approach
can be implemented. One of the examples illustrated a
query for (inferred) perturbagens with a defined activity
profile. As BAO includes class hierarchies for target,
design, detection technology, etc., perturbagen sub-classes
of interest may be directly defined in the ontology using
the same approach; e.g. “compounds promiscuously active
in luciferase reporter gene assays”. Using a reasoning
engine, the individuals that are members of such a class
could be automatically inferred among the currently anno-
tated assays. We are continuing to refine and extend the
BAO and supporting software. We have already created a
web portal with an easy-to-use querying interface that
incorporates some of the described functionality [32]. A
user can query PubChem data using BAO terminology
and collect sets of results for further analysis. It also allows
end users to formulate their own queries via a graphical
user interface. Future developments will include an anno-
tation tool for domain experts that will aid in the curation
process and the incorporation of additional data sources.
Methods
Ontology development
The development of ontologies, the annotation of docu-
ments and data with terms from various ontologies as well
as the use of ontologies can be complex, cumbersome, and
confusing. Thus, researchers have spent a good portion of
the last decade to develop supporting tools. They can be
classified into the following three categories:
Ontology construction
There exist whole suites, e.g. OntoStudio, NeOn Toolkit
and single editors, e.g. Protégé [33]. In addition, systems
for visualizing ontologies [34] and methods to analyze
ontologies [35] have been developed. Their primarily
purpose is not the construction of ontologies. However, a
large ontology can be very complex so that analysis/
visualization tools are necessary or at least helpful
throughout the development process. To construct BAO,
we used Protégé version 4.1. We used OWLViz [36] for
visualization and Pellet [37] as an appropriate DL reason-
ing engine. We used OntoFox [38] and the OWL API
[39] to extract and integrate modules from external
ontologies such as Gene Ontology (GO), NCBI Taxon-
omy, Cell Line Ontology (CLO) into BAO. Namespaces
of these external ontologies were preserved.
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There is a large variety of special query languages available
[40]. Prominent query languages cover queries for the tra-
ditional web (XML data), and for the Semantic Web (i.e.
mostly RDF data). Examples for the former are XPath [41]
or XQuery [42]), examples for the latter are RQL [43] or
SPARQL [44]). Languages targeting OWL (e.g. SWRL
[45]) are becoming more and more important and will
also be used in the future. However, for the work pre-
sented here our main query language was SPARQL. The
reason for this choice was the vast amount of data we had
to operate on. We used a RDF triple store with millions of
data records. The triple store consisted of the inferred
model of our domain, i.e. the asserted and inferred factual
knowledge. SPARQL is currently the best query language
for triple stores, because it can be used to express queries
across diverse data sources, whether the data are stored
natively as RDF or viewed as RDF via middleware.
Researchers can choose from a number of powerful infer-
ence engines that have been developed over the past few
years. Some ontology editors such as Protégé come with
integrated inference engines (Pellet), but also can be oper-
ated with alternative systems. Prominent and state-of-the-
art examples are HermiT [46], Pellet, Racer [47], and FaCT
++ [48]. All of them are DL reasoning engines that have
been proven to be sound and complete. Differences lay in
reasoning capabilities, performance and expressivity [48].
Further tools
These include API’s, proof tools and special programs:
APIs are useful if researchers would like to use existing or
developed ontologies and the reasoning capabilities of the
DL engines and combine them with their own software.
Prominent examples are OWL API [39] for working with
OWL 2 ontologies, the Thea-Prolog-OWL-Library [49]
that uses SWI Prolog’s RDF library or the Jena API [50],
which is a Java framework for building Semantic Web
applications. It provides an environment for RDF, RDFS
and OWL, SPARQL and also includes a rule-based infer-
ence engine. We used the Jena-API and the Jena SDB
component, because it provides means for large scale sto-
rage and queries of RDF datasets.
Curation of assay data
In an effort to make the PubChem data amenable to large-
scale computational analysis, we manually curated the
bioassays. Detailed information were captured from each
individual assay based on BAO classes, which fall into the
main categories format, meta target, design, detection
technology, perturbagen (at this point we only consider
small molecule compounds), endpoint, and general assays
characteristics. The annotations from each assay were
populated in a spreadsheet, cross checked, and then
loaded onto a triple store after merging with the relevant
PubChem endpoint data using the ontology as described
above. In addition to the bioassays run at the MLPCN,
PubChem houses data from other sources. Most notable is
the recent (October 2010) deposition of ~460,000 assay
records from the ChEMBL database. We are in the pro-
cess of incorporating these datasets into BAO.
Implementation and application
The ontology was used to facilitate the featured search
queries. Our “BAOSearch” is an application for querying,
viewing, browsing and downloading diverse high-through-
put screening (HTS) data for drug discovery and related
life science research [32]. BAOSearch is a multi-tier, web-
based, AJAX-enabled application written primarily in Java
and built following a Restful [51] web services paradigm.
The service-based aspect of the architecture allows the
user interface (UI) to be separated from storage and
manipulation of the data, and provides well-defined inter-
faces for UI components to access and manipulate applica-
tion data. This separation of application components
creates the potential of developing multiple UIs that access
the same service, but which render the data differently, or
run on different platforms (e.g., browsers, mobile applica-
tions). This architecture also creates an opportunity for
other software applications (not only UIs) to access the
system to query and retrieve data. The browser-based UI
was built using JSP and JavaScript, with components from
several JavaScript libraries including jQuery [52]. All data
were stored in a MySQL database. SDB [53] was used as
the triple-store. Other data required by the application
was stored in a relational schema accessible using Hiber-
nate. Figure 6 shows the high-level architecture of the
BAOSearch project.
Figure 6 High-level architecture of BAOSearch.
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